Use of blinatumomab and CAR T-cell therapy in children with relapsed/refractory leukemia: A case series study

Use of blinatumomab and CAR T-cell therapy in children with relapsed/refractory leukemia: A case series study

BackgroundThe 5-year event-free survival rate for childhood acute lymphoblastic leukemia (ALL) has increased to more than 85%. However, the 5-year overall survival rate in children with relapsed/refractory ALL did not exceed 50%. In the past decade, immunotherapies (such as blinatumomab and chimeric...

Full description

Bibliographic Details
Main Authors: Songmi Wang, Aiguo Liu, Na Wang, Yaqin Wang, Ai Zhang, Li Wang, Wen Yu, Chunrui Li, Yicheng Zhang, Qun Hu
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Pediatrics
Subjects:
acute leukemia
pediatric
immunotherapy
blinatumomab
chimeric antigen receptor T cells
Online Access:https://www.frontiersin.org/articles/10.3389/fped.2022.1100404/full

Internet

https://www.frontiersin.org/articles/10.3389/fped.2022.1100404/full

Similar Items